Herceptin (Breast Cancer) Analysis and Forecasts to 2020


#28314

54pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Herceptin (Breast Cancer) Analysis and Forecasts to 2020 provides Herceptin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Herceptin including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Herceptin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2020 for Herceptin in the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Report Guidance 7


3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 9
3.3.4 Decreasing Breast Cancer Mortality Rate 11
3.3.5 High Survival Rates of Breast Cancer 13


4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15


5 Predictive Biomarker in the Treatment of Breast Cancer 18


6 Treatment Options of Breast Cancer 20
6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 27


7 Herceptin 29
7.1 Introduction 29
7.2 Mechanism of Action 29
7.3 Approved Indications 29
7.3.1 Early Breast Cancer 29
7.3.2 Advanced (metastatic) Breast Cancer 29
7.4 Clinical Studies 30
7.5 Approval History of Herceptin 33
7.6 Factors Affecting Sales of Herceptin 34
7.6.1 Improved Efficacy 34
7.6.2 Low Competition 34
7.6.3 Niche Market 34
7.6.4 Approved for Both Early as well as Metastatic Stage 35
7.7 Drug Evaluation 35
7.7.1 Drug Risk Benefit Score 35
7.7.2 Intensity of Competition 38
7.8 Sales forecast 38
7.8.1 Target patient Pool of Herceptin 39
7.8.2 Dosing 39
7.8.3 Market Penetration 40
7.8.4 Annual Cost of Therapy 40
7.8.5 Sales Projections of Herceptin 40


8 Breast Cancer Market: Appendix 50
8.1 Market Definitions 50
8.2 List of Abberiviations 50
8.3 Research Methodology 50
8.3.1 Coverage 50
8.3.2 Secondary Research 51
8.3.3 Forecasting 51
8.3.4 Number of Patients Approved to take the Drug 51
8.3.5 Net Penetration of Drug 52
8.3.6 Net Annual Dosing 53
8.3.7 Annual Cost of Therapy 53
8.3.8 Primary Research 53
8.3.9 Expert Panels 53
8.4 Contact Us 54
8.5 Disclaimer 54
8.6 Sources 54


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Table 3: Five-Year Relative Survival Rates, By Stages 14
Table 4: Herceptin as a Combination Therapy 30
Table 5: Herceptin as a monotherapy 31
Table 6: Results of TAnDEM study 31
Table 7: Comparison of Herceptin plus Anthracycline with Anthracycline alone 32
Table 8: Comparison of Herceptin plus Paclitaxel with Paclitaxel alone 32
Table 9: Comparison of Herceptin plus Docetaxel with Docetaxel alone 33
Table 10: Results of Herceptin as a monotherapy 33
Table 11: Patent Approval of Herceptin 33
Table 12: Approval History of Herceptin 34
Table 13: Drug Risk Benefit Score of Herceptin as a monotherapy 35
Table 14: Drug Risk Benefit Score of Herceptin as a Combination Therapy 35
Table 15: Drug Risk Benefit Score of Herceptin as a First Line Treatment 36
Table 16: Drug Risk Benefit Score of Herceptin as a Second Line Treatment 36
Table 17: Drug Risk Benefit Score of Herceptin as a Third Line Treatment 36
Table 18: Herceptin , Breast Cancer, the US, EU-5 and Japan, Sales Estimates ($bn), 20022020 41
Table 19: Herceptin , Breast Cancer, The US, Sales Estimates ($bn), 20022020 43
Table 20: Herceptin , Breast Cancer, The UK, Sales Estimates ($bn), 20022020 44
Table 21: Herceptin, Breast Cancer, France, Sales Estimates ($bn), 20022020 45
Table 22: Herceptin , Breast Cancer, Germany, Sales Estimates ($bn), 20022020 46
Table 23: Herceptin, Breast Cancer, Italy, Sales Estimates ($bn), 20022020 47
Table 24: Herceptin , Breast Cancer, Spain, Sales Estimates ($bn), 20022020 48
Table 25: Herceptin, Breast Cancer, Japan, Sales Estimates ($bn), 20022020 49


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top 10 Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 12: Broad Classification of Breast Cancer, By Type 15
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 14: Classification of Invasive Breast Cancer, By Stages 16
Figure 15: Classification of Invasive Breast Cancer, By Treatment 16
Figure 16: Classification of Metastatic or Advanced Breast Cancer 16
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17
Figure 18: Classification of Locally Advanced Breast Cancer 17
Figure 19: Metastatic Breast Cancer Classification 17
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 21: Breast Cancer Intrinsic Sub Types used for deciding Treatment Options for MBC 19
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 23: Treatment Options, DCIS Breast Cancer 20
Figure 24: Treatment Options, LCIS Breast Cancer 21
Figure 25: Treatment Options, Stages I, II and IIIA 21
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27
Figure 33: Survival Comparison of Herceptin in Combination Therapy 37
Figure 34: Survival Comparison of Herceptin in Monotherapy 37
Figure 35: Drug Model Diagram of Herceptin in the US, EU-5 and Japan 39
Figure 36: Herceptin , Breast Cancer, the US, EU-5 and Japan, Sales Estimates ($bn), 20022020 41
Figure 37: Breast Cancer, Global, Herceptin Sales Distribution, 2020 42
Figure 38: Herceptin , Breast Cancer, The US, Sales Estimates ($bn), 20022020 43
Figure 39: Herceptin , Breast Cancer, The UK, Sales Estimates ($bn), 20022020 44
Figure 40: Herceptin , Breast Cancer, France, Sales Estimates ($bn), 20022020 45
Figure 41: Herceptin , Breast Cancer, Germany, Sales Estimates ($bn), 20022020 46
Figure 42: Herceptin , Breast Cancer, Italy, Sales Estimates ($bn), 20022020 47
Figure 43: Herceptin , Breast Cancer, Spain, Sales Estimates ($bn), 20022020 48
Figure 44: Herceptin, Breast Cancer, Japan, Sales Estimates ($bn), 2002-2020 49
Figure 45: Drug Model Diagram 52
Figure 46: Patients Approved for the Drug 53